Ray, that is true to a point. But step back from that for a moment and ask why if there are clearly a number of very positive developments and an increase in national and international awareness of the developing and existing products that the share price "goes down" on the news. I think you understand the reasons for that and they have to do with interests external to the Company and actual investors.
I would like to see wonderful earnings figures also, but I also understand that the Company is building a substantial and diverse base of customers that ultimately will provide a strong and continuing foundation. As far as I can tell NanoLogix is selling to Battelle, the Defense industry, the EPA, Ohio State and other universities in the US and abroad, several cosmetic companies of great size and potential, a high-end grocery chain, users of packaged and long lasting petri plates and I am certain more.
I suggested to a veterinarian I know that an N-Assy template could be designed for the most common test areas they deal with and the person immediately beme excited about the prospect and began spouting types of infections for which it could be perfect. This could represent a very substantial market for NanoLogix because there are thousands of vet practices that right now have to ship testing out to labs. It could become a money maker for a number of the practices.
Rather than having all its "eggs" in one basket it is developing a variety of sustainable customers. I think that is a healthy sign for the Company. I also hope the deals signed with the Singaporean and Saudi companies work to our benefit but having done considerable work outside the US I admit that it is not easy to deal with the opacity of how your "partners" collaborate with you.
In addition to the above, I really think the emerging potential of the N-Assay in the neonatal and MRSA areas, and now in relation to viruses represents something with enormous potential. We have to hope that some "deep pocket" does partner with NanoLogix in the N-Assay (V) context and that something similar occurs in relation to the bacterial N-Assay because there really is an issue of scale for marketing, manufacturing and distribution. The developing earnings situation on a widening customer base is important but so is being able to service the scale of the markets for which the N-Assay products are being designed.
I would like to see wonderful earnings figures also, but I also understand that the Company is building a substantial and diverse base of customers that ultimately will provide a strong and continuing foundation. As far as I can tell NanoLogix is selling to Battelle, the Defense industry, the EPA, Ohio State and other universities in the US and abroad, several cosmetic companies of great size and potential, a high-end grocery chain, users of packaged and long lasting petri plates and I am certain more.
I suggested to a veterinarian I know that an N-Assy template could be designed for the most common test areas they deal with and the person immediately beme excited about the prospect and began spouting types of infections for which it could be perfect. This could represent a very substantial market for NanoLogix because there are thousands of vet practices that right now have to ship testing out to labs. It could become a money maker for a number of the practices.
Rather than having all its "eggs" in one basket it is developing a variety of sustainable customers. I think that is a healthy sign for the Company. I also hope the deals signed with the Singaporean and Saudi companies work to our benefit but having done considerable work outside the US I admit that it is not easy to deal with the opacity of how your "partners" collaborate with you.
In addition to the above, I really think the emerging potential of the N-Assay in the neonatal and MRSA areas, and now in relation to viruses represents something with enormous potential. We have to hope that some "deep pocket" does partner with NanoLogix in the N-Assay (V) context and that something similar occurs in relation to the bacterial N-Assay because there really is an issue of scale for marketing, manufacturing and distribution. The developing earnings situation on a widening customer base is important but so is being able to service the scale of the markets for which the N-Assay products are being designed.
